You can buy or sell TCON and other stocks, options, ETFs, and crypto commission-free!
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types; TRC205 created for the treatment of fibrotic diseases; and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. Read More The company was founded in October 2004 and is headquartered in San Diego, CA.
San Diego, California
52 Week High
52 Week Low
Markets InsiderMay 7
TRACON to Report First Quarter 2019 Company Highlights and Financial Results on May 14, 2019
SAN DIEGO, May 07, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and, through our license to Santen Pharmaceutical Co. Ltd.
-$0.21 per share
-$0.24 per share